# Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

> **NCT00664534** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 344 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Glargine
- **DRUG:** Insulin Lispro Premix (mid-mixture and low-mixture)

## Key facts

- **NCT ID:** NCT00664534
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2011-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664534, "Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00664534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*